You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A NOVEL RF TENS DEVICE FOR ACUTE PAIN MANAGEMENT

    SBC: CYCLOTEC ADVANCED MEDICAL TECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): Cyclotec AMT, Inc. is developing 'non-invasive' transcutaneous electrical stimulators (TENS) that may prove to be viable adjuncts to or alternatives for drugs for management of recent onset "acute" pain. TENS has long been used for "chronic" pain management. The device complexities have made them prohibitive for short-term 'acute' applications; an application ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. DIAGNOSTIC FLOW CYTOMETRY

    SBC: FLOW-AMP SYSTEMS, LTD            Topic: N/A

    DESCRIPTION (provided by applicant)Hepatitis C virus infection is a chronic disease that inflicts 170 million people worldwide. Infection usually results in a persistent hepatitis that can lead to cirrhosis and/or hepatocellular carcinoma. Moreover, chronic infection is associated with a number of adverse complications including lymphoma and autoimmune phenomena.Besides hepatocytes, the virus has ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. NOVEL DOXORUBICIN ANALOGS:CARDIAC AND CYTOTOXIC EFFECTS

    SBC: GEM Pharmaceuticals            Topic: N/A

    Anthracyclines such as doxorubicin and daunorubicin are valuable anti- cancer drugs but their clinical utility is compromised by cumulative dose-dependent by a cumulative dose dependent cardiotoxicity. Anthracycline cardiotoxicity has been linked to free radical damage via mechanisms that involve disruption of iron regulation and formation of superoxide anion. Although the quinone moiety of anthra ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  4. NOVEL DOXORUBICIN ANALOGS:CARDIAC AND CYTOTOXIC EFFECTS

    SBC: GEM Pharmaceuticals            Topic: N/A

    Anthracyclines such as doxorubicin and daunorubicin are valuable anti- cancer drugs but their clinical utility is compromised by cumulative dose-dependent by a cumulative dose dependent cardiotoxicity. Anthracycline cardiotoxicity has been linked to free radical damage via mechanisms that involve disruption of iron regulation and formation of superoxide anion. Although the quinone moiety of anthra ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. CYTOTOXIC GONADOTROPIN RELEASING HORMONE DERIVATIVES

    SBC: GONEX, INC.            Topic: N/A

    Hormonally responsive cancers, such as prostate and breast, are a major cause of morbidity and mortality in the aging population in the United States. These cancers can be treated by sex steroid antagonists by these compounds are costly and mutational escape occurs. Recent innovative approaches have used hormonotoxins to specifically target the cancer cells. Several such approaches are already in ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. SOCIAL COMPETENCE IN FAMILY CHILD CARE SETTINGS

    SBC: IRIS MEDIA INC            Topic: N/A

    DESCRIPTION (provided by investigator): The quality or experiences in child care has significant, lasting impact on children's social development and early efforts are essential for preventing the progression of conduct problems in youth. The purpose of this proposed project is to develop a video-based training program and manual for family child care providers in strategies for facilitating chil ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. M3 RECEPTOR--DIAGNOSTIC MARKER FOR SJOGREN'S SYNDROME

    SBC: IXION BIOTECHNOLOGY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Sjogren's syndrome is a human autoimmune disease of the salivary and lacrimal glands that results in a debilitating xerostomia (dry mouth) and xerophthalmia (dry eyes). This syndrome may present as either a primary autoimmune disease or as a secondary autoimmune disease most often concomitant with other connective tissue diseases or diabetes. Although classi ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. M3 RECEPTOR--DIAGNOSTIC MARKER FOR SJOGREN'S SYNDROME

    SBC: IXION BIOTECHNOLOGY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Sjogren's syndrome is a human autoimmune disease of the salivary and lacrimal glands that results in a debilitating xerostomia (dry mouth) and xerophthalmia (dry eyes). This syndrome may present as either a primary autoimmune disease or as a secondary autoimmune disease most often concomitant with other connective tissue diseases or diabetes. Although classi ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  9. NOVEL BISPHOSPHONATES FOR BREAST CANCER THERAPY

    SBC: MBC Pharma, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Bisphosphonates are currently used as bone-specific palliative treatments for metastatic bone disease in multiple myeloma and breast cancer patients. However, bisphosphonate use has no proven impact on primary tumor burden and overall survival and only moderately reduces skeletal complications. Bisphosphonate conjugates were synthesized using proprietary techn ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. TARGETED DELIVERY OF ESTROGEN IN MENOPAUSE

    SBC: MOLECULAR DIAGNOSTICS LABORATORIES, INC.            Topic: N/A

    In postmenopausal women, coronary artery disease (CAD) is the leading cause of death. Estrogen replacement therapy appears to offer considerable protection against CAD in postmenopausal women. However, there is great concern about risk for breast and endometrial cancer after long-term estrogen use in these women. The activation of estrogen receptors and subsequent genomic effects in terms of cell ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government